Benzinga | Feb 25, 2021 07:28AM EST

Needham Assumes NeoGenomics at Buy, Announces Price Target of $65

Needham analyst Mike Matson assumes NeoGenomics (NASDAQ:NEO) with a Buy rating and announces Price Target of $65.